{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rotroff DM"],"funding":["NIDDK NIH HHS","NIA NIH HHS","National Heart, Lung, and Blood Institute","NHLBI NIH HHS","Medical Research Council","National Institutes of Health","NIAMS NIH HHS","Wellcome Trust","NIGMS NIH HHS"],"pagination":["1428-1440"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6014560"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["67(7)"],"pubmed_abstract":["Metformin is the first-line treatment for type 2 diabetes (T2D). Although widely prescribed, the glucose-lowering mechanism for metformin is incompletely understood. Here, we used a genome-wide association approach in a diverse group of individuals with T2D from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial to identify common and rare variants associated with HbA<sub>1c</sub> response to metformin treatment and followed up these findings in four replication cohorts. Common variants in <i>PRPF31</i> and <i>CPA6</i> were associated with worse and better metformin response, respectively (<i>P</i> < 5 × 10<sup>-6</sup>), and meta-analysis in independent cohorts displayed similar associations with metformin response (<i>P</i> = 1.2 × 10<sup>-8</sup> and <i>P</i> "],"journal":["Diabetes"],"pubmed_title":["Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes."],"pmcid":["PMC6014560"],"funding_grant_id":["GM117163","HDR-5006","GM61390","U01 GM061390","R01 GM117163","R01 HL110400","5R01HL110380-04","R00 AG047255","R01 HL110380","102820/Z/13/Z","P30 DK036836","U19 GM061390","R01 AR073017"],"pubmed_authors":["Rotroff DM","Motsinger-Reif AA","McLeod HL","Havener TM","Doria A","Herman MA","Gao H","Shah HS","Marvel SW","Giacomini KM","Wagner MJ","Yee SW","Pearson ER","Buse JB","Mychaleckyi JC","MetGen Investigators","ACCORD/ACCORDion Investigators","Hedderson MM","Zhou K","Jack JR","Kubo M"],"additional_accession":[]},"is_claimable":false,"name":"Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.","description":"Metformin is the first-line treatment for type 2 diabetes (T2D). Although widely prescribed, the glucose-lowering mechanism for metformin is incompletely understood. Here, we used a genome-wide association approach in a diverse group of individuals with T2D from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial to identify common and rare variants associated with HbA<sub>1c</sub> response to metformin treatment and followed up these findings in four replication cohorts. Common variants in <i>PRPF31</i> and <i>CPA6</i> were associated with worse and better metformin response, respectively (<i>P</i> < 5 × 10<sup>-6</sup>), and meta-analysis in independent cohorts displayed similar associations with metformin response (<i>P</i> = 1.2 × 10<sup>-8</sup> and <i>P</i> ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jul","modification":"2026-04-30T17:53:52.614Z","creation":"2019-07-24T07:21:39Z"},"accession":"S-EPMC6014560","cross_references":{"pubmed":["29650774"],"doi":["10.2337/db17-1164"]}}